Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort.

Holst JM, Plesner TL, Pedersen MB, Frederiksen H, Møller MB, Clausen MR, Hansen MC, Hamilton-Dutoit SJ, Nørgaard P, Johansen P, Eberlein TR, Mortensen BK, Mathiasen G, Øvlisen A, Wang R, Wang C, Zhang W, Ommen HB, Stentoft J, Ludvigsen M, Tam W, Chan WC, Inghirami G, d'Amore F.

Haematologica. 2019 Nov 28. pii: haematol.2019.225839. doi: 10.3324/haematol.2019.225839. [Epub ahead of print]

2.

Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Turner SD, Inghirami G, Miranda RN, Kadin ME.

Am J Pathol. 2019 Oct 11. pii: S0002-9440(19)30753-9. doi: 10.1016/j.ajpath.2019.09.005. [Epub ahead of print] Review.

3.

Does Breast Implant Associated ALCL begin as a Lymphoproliferative Disorder?

Kadin ME, Adams WP Jr, Inghirami G, Di Napoli A.

Plast Reconstr Surg. 2019 Sep 30. doi: 10.1097/PRS.0000000000006390. [Epub ahead of print]

PMID:
31577659
4.

Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.

Laginestra MA, Cascione L, Motta G, Fuligni F, Agostinelli C, Rossi M, Sapienza MR, Righi S, Broccoli A, Indio V, Melle F, Tabanelli V, Calleri A, Novero D, Facchetti F, Inghirami G, Sabattini E, Bertoni F, Pileri SA.

Mod Pathol. 2019 Sep 26. doi: 10.1038/s41379-019-0376-8. [Epub ahead of print]

PMID:
31558781
5.

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen CW, Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, Kwak LW.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw9414. doi: 10.1126/scitranslmed.aaw9414.

PMID:
31554741
6.

Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets.

Etebari M, Navari M, Agostinelli C, Visani A, Peron C, Iqbal J, Inghirami G, Piccaluga PP.

Front Genet. 2019 Sep 10;10:780. doi: 10.3389/fgene.2019.00780. eCollection 2019.

7.

Repurposing dasatinib for diffuse large B cell lymphoma.

Scuoppo C, Wang J, Persaud M, Mittan SK, Basso K, Pasqualucci L, Rabadan R, Inghirami G, Grandori C, Bosch F, Dalla-Favera R.

Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16981-16986. doi: 10.1073/pnas.1905239116. Epub 2019 Aug 5.

PMID:
31383760
8.

Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.

Della Starza I, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, Menale L, Soscia R, Apicella V, Ilari C, Vitale A, Testi AM, Inghirami G, Chiaretti S, Foà R, Guarini A.

Leuk Lymphoma. 2019 Nov;60(11):2838-2840. doi: 10.1080/10428194.2019.1607325. Epub 2019 May 3. No abstract available.

PMID:
31050551
9.

Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.

Laginestra MA, Cascione L, Motta G, Fuligni F, Agostinelli C, Rossi M, Sapienza MR, Righi S, Broccoli A, Indio V, Melle F, Tabanelli V, Calleri A, Novero D, Facchetti F, Inghirami G, Sabattini E, Bertoni F, Pileri SA.

Mod Pathol. 2019 Apr 25. doi: 10.1038/s41379-019-0279-8. [Epub ahead of print] Erratum in: Mod Pathol. 2019 Sep 26;:.

PMID:
31028364
10.

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz S.

Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220. Epub 2019 Apr 18. No abstract available.

PMID:
30997845
11.

Author Correction: The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.

Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, Okada M, Viale A, Heguy A, Socci ND, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG.

Nat Cell Biol. 2019 Apr;21(4):534. doi: 10.1038/s41556-019-0288-3.

PMID:
30842593
12.

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.

Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan WC, Dodero A, Carniti C, Heavican TB, Pellegrinelli A, Pruneri G, Butler A, Bhosle SG, Chiappella A, Di Rocco A, Zinzani PL, Zaja F, Piva R, Inghirami G, Wang W, Palomero T, Iqbal J, Neri A, Campbell PJ, Corradini P.

Am J Hematol. 2019 Jun;94(6):628-634. doi: 10.1002/ajh.25450. Epub 2019 Mar 19.

13.

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairismägi ML, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Missiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d'Amore F, Inghirami G, Bertoni F, de Leval L, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J.

Blood. 2019 Apr 11;133(15):1664-1676. doi: 10.1182/blood-2018-09-872549. Epub 2019 Feb 19.

PMID:
30782609
14.

Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death.

Garcia-Bermudez J, Baudrier L, Bayraktar EC, Shen Y, La K, Guarecuco R, Yucel B, Fiore D, Tavora B, Freinkman E, Chan SH, Lewis C, Min W, Inghirami G, Sabatini DM, Birsoy K.

Nature. 2019 Mar;567(7746):118-122. doi: 10.1038/s41586-019-0945-5. Epub 2019 Feb 13.

15.

Elliptic flow and R AA of D mesons at FAIR comparing the UrQMD hybrid model and the coarse-graining approach.

Inghirami G, van Hees H, Endres S, Torres-Rincon JM, Bleicher M.

Eur Phys J C Part Fields. 2019;79(1):52. doi: 10.1140/epjc/s10052-019-6537-6. Epub 2019 Jan 21.

16.

The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3.

Gambi G, Di Simone E, Basso V, Ricci L, Wang R, Verma A, Elemento O, Ponzoni M, Inghirami G, Icardi L, Mondino A.

Cancer Res. 2019 Jun 15;79(12):3076-3087. doi: 10.1158/0008-5472.CAN-18-0359. Epub 2019 Jan 28.

PMID:
30692217
17.

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.

Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling L, Dittus C, Chen Z, Huang X, Inghirami G, DiLiberto M, Chen-Kiang S, Leonard JP.

Blood. 2019 Mar 14;133(11):1201-1204. doi: 10.1182/blood-2018-11-886457. Epub 2019 Jan 28. Erratum in: Blood. 2019 Sep 12;134(11):908.

PMID:
30692121
18.

Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis.

Hatzi K, Geng H, Doane AS, Meydan C, LaRiviere R, Cardenas M, Duy C, Shen H, Vidal MNC, Baslan T, Mohammad HP, Kruger RG, Shaknovich R, Haberman AM, Inghirami G, Lowe SW, Melnick AM.

Nat Immunol. 2019 Jan;20(1):86-96. doi: 10.1038/s41590-018-0273-1. Epub 2018 Dec 10.

19.

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS.

Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.

20.

Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells.

Russo V, Paciocco A, Affinito A, Roscigno G, Fiore D, Palma F, Galasso M, Volinia S, Fiorelli A, Esposito CL, Nuzzo S, Inghirami G, de Franciscis V, Condorelli G.

Mol Ther Nucleic Acids. 2018 Dec 7;13:334-346. doi: 10.1016/j.omtn.2018.09.016. Epub 2018 Sep 27.

21.

TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.

Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontán L, Rivas MA, Pawlikowska P, Armand M, Mouly E, Torres-Martin M, Doane AS, Calvo Fernandez MT, Durant M, Della-Valle V, Teater M, Cimmino L, Droin N, Tadros S, Motanagh S, Shih AH, Rubin MA, Tam W, Aifantis I, Levine RL, Elemento O, Inghirami G, Green MR, Figueroa ME, Bernard OA, Aoufouchi S, Li S, Shaknovich R, Melnick AM.

Cancer Discov. 2018 Dec;8(12):1632-1653. doi: 10.1158/2159-8290.CD-18-0657. Epub 2018 Oct 1.

22.

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL.

Cheng S, Inghirami G, Cheng S, Tam W.

J Hematol Oncol. 2018 Aug 22;11(1):105. doi: 10.1186/s13045-018-0652-y.

23.

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O.

Leukemia. 2019 Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. Epub 2018 Aug 21.

PMID:
30131584
24.

PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.

Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontán L, Durant M, Geng H, Melnick J, Luo Y, Vega F, Moy V, Inghirami G, Nimer S, Melnick AM, Lossos IS.

Blood. 2018 Nov 8;132(19):2026-2039. doi: 10.1182/blood-2018-02-831438. Epub 2018 Aug 6.

25.

Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.

Fontán L, Qiao Q, Hatcher JM, Casalena G, Us I, Teater M, Durant M, Du G, Xia M, Bilchuk N, Chennamadhavuni S, Palladino G, Inghirami G, Philippar U, Wu H, Scott DA, Gray NS, Melnick A.

J Clin Invest. 2018 Oct 1;128(10):4397-4412. doi: 10.1172/JCI99436. Epub 2018 Jul 19.

26.

Patient derived organoids to model rare prostate cancer phenotypes.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H.

Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z.

27.

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.

Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A Jr, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R.

Nat Commun. 2018 May 22;9(1):2024. doi: 10.1038/s41467-018-04356-9.

28.

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

Chiaretti S, Messina M, Grammatico S, Piciocchi A, Fedullo AL, Di Giacomo F, Peragine N, Gianfelici V, Lauretti A, Bareja R, Martelli MP, Vignetti M, Apicella V, Vitale A, Li LS, Salek C, Elemento O, Inghirami G, Weinstock DM, Guarini A, Foà R.

Br J Haematol. 2018 Jun;181(5):642-652. doi: 10.1111/bjh.15251. Epub 2018 Apr 19.

29.

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, Brusa D, Deaglio S, Chiaretti S, Bruna R, Gottardi D, Massaia M, Giacomo FD, Guarini AR, Foà R, Kyriakides PW, Bareja R, Elemento O, Chichili GR, Monteleone E, Moore PA, Johnson S, Bonvini E, Cignetti A, Inghirami G.

Oncoimmunology. 2018 Feb 8;7(4):e1341032. doi: 10.1080/2162402X.2017.1341032. eCollection 2018.

30.

Pathogenesis of Peripheral T Cell Lymphoma.

Pizzi M, Margolskee E, Inghirami G.

Annu Rev Pathol. 2018 Jan 24;13:293-320. doi: 10.1146/annurev-pathol-020117-043821. Review.

PMID:
29414251
31.

Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma.

Tabbò F, Nottegar A, Guerrera F, Migliore E, Luchini C, Maletta F, Veronese N, Montagna L, Gaudiano M, Di Giacomo F, Filosso PL, Delsedime L, Ciccone G, Scarpa A, Sapino A, Oliaro A, Ruffini E, Inghirami G, Chilosi M.

Hum Pathol. 2018 May;75:167-178. doi: 10.1016/j.humpath.2018.01.017. Epub 2018 Jan 31.

PMID:
29409837
32.

IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.

Bandini C, Pupuleku A, Spaccarotella E, Pellegrino E, Wang R, Vitale N, Duval C, Cantarella D, Rinaldi A, Provero P, Di Cunto F, Medico E, Bertoni F, Inghirami G, Piva R.

Cancers (Basel). 2018 Jan 18;10(1). pii: E21. doi: 10.3390/cancers10010021.

33.

AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis.

Teater M, Dominguez PM, Redmond D, Chen Z, Ennishi D, Scott DW, Cimmino L, Ghione P, Chaudhuri J, Gascoyne RD, Aifantis I, Inghirami G, Elemento O, Melnick A, Shaknovich R.

Nat Commun. 2018 Jan 15;9(1):222. doi: 10.1038/s41467-017-02595-w.

34.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ.

Cancer Res. 2017 Nov 1;77(21):e62-e66. doi: 10.1158/0008-5472.CAN-17-0582.

35.

Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data.

Gong Q, Wang C, Zhang W, Iqbal J, Hu Y, Greiner TC, Cornish A, Kim JH, Rabadan R, Abate F, Wang X, Inghirami GG, McKeithan TW, Chan WC.

Sci Rep. 2017 Sep 12;7(1):11301. doi: 10.1038/s41598-017-11310-0.

36.

Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.

Cascione L, Rinaldi A, Chiappella A, Kwee I, Ciccone G, Altenbuchinger M, Kohler C, Vitolo U, Inghirami G, Bertoni F.

Br J Haematol. 2018 Aug;182(3):453-456. doi: 10.1111/bjh.14817. Epub 2017 Jul 24. No abstract available.

PMID:
28737236
37.

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.

Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S.

Nat Commun. 2017 Jun 9;8:15618. doi: 10.1038/ncomms15618.

38.

Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease?

Pizzi M, Inghirami G.

Curr Opin Hematol. 2017 Jul;24(4):384-392. doi: 10.1097/MOH.0000000000000349. Review.

PMID:
28594662
39.

Are we ready to take full advantage of patient-derived tumor xenograft models?

Kyriakides PW, Inghirami G.

Hematol Oncol. 2018 Feb;36(1):24-27. doi: 10.1002/hon.2419. Epub 2017 May 23. No abstract available.

PMID:
28543217
40.

Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis.

Nottegar A, Tabbò F, Luchini C, Guerrera F, Gaudiano M, Bria E, Brunelli M, Chilosi M, Inghirami G.

Exp Mol Pathol. 2017 Apr;102(2):276-279. doi: 10.1016/j.yexmp.2017.02.014. Epub 2017 Feb 22.

PMID:
28237660
41.

Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, Roman L, Gaudiano M, Crescenzo R, Ruan J, Inghirami G, Zhang T, Cremaschi G, Gray NS, Cerchietti L.

Nat Commun. 2017 Feb 20;8:14747. doi: 10.1038/ncomms14747. No abstract available.

42.

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, Roman L, Gaudiano M, Crescenzo R, Ruan J, Inghirami G, Zhang T, Cremaschi G, Gray NS, Cerchietti L.

Nat Commun. 2017 Jan 30;8:14290. doi: 10.1038/ncomms14290.

43.

Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.

Abate F, da Silva-Almeida AC, Zairis S, Robles-Valero J, Couronne L, Khiabanian H, Quinn SA, Kim MY, Laginestra MA, Kim C, Fiore D, Bhagat G, Piris MA, Campo E, Lossos IS, Bernard OA, Inghirami G, Pileri S, Bustelo XR, Rabadan R, Ferrando AA, Palomero T.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):764-769. doi: 10.1073/pnas.1608839114. Epub 2017 Jan 6.

44.

The heterogeneous landscape of ALK negative ALCL.

Mereu E, Pellegrino E, Scarfò I, Inghirami G, Piva R.

Oncotarget. 2017 Mar 14;8(11):18525-18536. doi: 10.18632/oncotarget.14503. Review.

45.

Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells.

Cao Z, Scandura JM, Inghirami GG, Shido K, Ding BS, Rafii S.

Cancer Cell. 2017 Jan 9;31(1):110-126. doi: 10.1016/j.ccell.2016.11.010. Epub 2016 Dec 15.

46.

Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment.

Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen SS, Arruga F, Brusa D, Coscia M, Jaksic O, Inghirami G, Rossi D, Furman RR, Robson SC, Gaidano G, Chiorazzi N, Deaglio S.

Blood Adv. 2016 Nov 22;1(1):47-61. doi: 10.1182/bloodadvances.2016000984. eCollection 2016 Nov 29.

47.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.

Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G, D'Incalci M, Noel K, Cvitkovic E, Raymond E, Bertoni F.

Oncotarget. 2016 Dec 20;7(51):84675-84687. doi: 10.18632/oncotarget.13181.

48.

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Boi M, Todaro M, Vurchio V, Yang SN, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M, Cerchietti L, Elemento O, Riveiro ME, Cvitkovic E, Bertoni F, Inghirami G; AIRC 5xMille Consortium ‘Genetics-Driven Targeted Management of Lymphoid Malignancies’.

Oncotarget. 2016 Nov 29;7(48):79637-79653. doi: 10.18632/oncotarget.12876.

49.

Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology.

Nottegar A, Tabbò F, Luchini C, Brunelli M, Bria E, Veronese N, Santo A, Cingarlini S, Gilioli E, Ogliosi C, Eccher A, Montagna L, Pedron S, Doglioni C, Cangi MG, Inghirami G, Chilosi M.

Appl Immunohistochem Mol Morphol. 2018 Jul;26(6):383-387. doi: 10.1097/PAI.0000000000000440.

PMID:
27753661
50.

Corrigendum: Stromal contribution to the colorectal cancer transcriptome.

Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, Mellano A, Senetta R, Cassenti A, Sonetto C, Inghirami G, Trusolino L, Fekete Z, De Ridder M, Cassoni P, Storme G, Bertotti A, Medico E.

Nat Genet. 2016 Sep 28;48(10):1296. doi: 10.1038/ng1016-1296d. No abstract available.

PMID:
27681291

Supplemental Content

Loading ...
Support Center